Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Steps Closer To Flu Market Domination With Phase III Baloxavir Results

Executive Summary

Not even a month after the FDA granted the antiviral Priority Review, baloxavir marboxil has shown superior efficacy in its primary endpoint in the latest CAPSTONE-2 Phase III clinical study, taking it closer to possible market supremacy for influenza A and B.


Related Content

Clinical Trials In Review: Big Hits And Misses In 2018
Roche's IMpassion130 Is First Positive Phase III Immunotherapy Study In Triple Negative Breast Cancer
Roche Pushes Personalization With $2.4bn Foundation Buy-Out
2017 Filing For Shionogi's Novel Flu Drug In Japan On Back Of Strong Phase III Data


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts